Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics (GB:0K1R)
LSE:0K1R
RESEARCH TOOLSreports
Holding GB:0K1R?
Track your performance easily
0K1R Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.50 - $27.10
Previous Close$19.18
Volume112.00
Average Volume (3M)2.59K
Market Cap
$1.53B
Enterprise Value$997.20M
Total Cash (Recent Filing)$552.92M
Total Debt (Recent Filing)$20.52M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
May 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.31
Shares Outstanding79,212,747
10 Day Avg. Volume5,382
30 Day Avg. Volume2,586
Standard Deviation0.30
R-Squared0.03
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)2.86
Price to Sales (P/S)5064.89
Price to Cash Flow (P/CF)-5.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.30K
Enterprise Value/Gross Profit3.18K
Enterprise Value/Ebitda-3.99
Forecast
1Y Price Target
$41.64Price Target Upside117.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Viridian Therapeutics News
PremiumCompany Announcements
Viridian Therapeutics Achieves Milestone in Phase 3 TrialBulls Say, Bears Say
Bulls Say
Efficacy And Clinical DifferentiationVeligrotug's diplopia benefit in chronic TED positions it for a differentiated claim in an eventual label.
Market PotentialCompelling efficacy and safety data enable veligrotug to capture a significant share in the TED market rapidly.
Safety And TolerabilityVeligrotug is generally well-tolerated with most adverse events being mild and a low discontinuation rate.
Bears Say
CatalystsThe lack of 2025 catalysts may cap upside.
Financial ImpactA miss could impact BLA submission timing, and could have a negative ~$15 impact on valuation.
Market CompetitionEntering the already crowded FcRn space is a big investment for Viridian and the onus will be on Viridian to demonstrate differentiation.
---
Options Prices
Currently, No data available
---
Ownership Overview
4.38% Insiders
21.66% Mutual Funds
60.26% Other Institutional Investors
1.01% Public Companies and
Individual Investors
0K1R FAQ
What was Viridian Therapeutics’s price range in the past 12 months?
Viridian Therapeutics lowest share price was $11.50 and its highest was $27.10 in the past 12 months.
What is Viridian Therapeutics’s market cap?
Currently, no data Available
When is Viridian Therapeutics’s upcoming earnings report date?
Viridian Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 132 days.
How were Viridian Therapeutics’s earnings last quarter?
Viridian Therapeutics released its earnings results on Nov 12, 2024. The company reported -$1.15 earnings per share for the quarter, missing the consensus estimate of -$1.057 by -$0.093.
Is Viridian Therapeutics overvalued?
According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued.
Does Viridian Therapeutics pay dividends?
Viridian Therapeutics does not currently pay dividends.
What is Viridian Therapeutics’s EPS estimate?
Viridian Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Viridian Therapeutics have?
Viridian Therapeutics has 79,212,746 shares outstanding.
What happened to Viridian Therapeutics’s price movement after its last earnings report?
Viridian Therapeutics reported an EPS of -$1.15 in its last earnings report, missing expectations of -$1.057. Following the earnings report the stock price went down -7.623%.
Which hedge fund is a major shareholder of Viridian Therapeutics?
Among the largest hedge funds holding Viridian Therapeutics’s share is Fairmount Funds Management Llc. It holds Viridian Therapeutics’s shares valued at 78M.
---
Viridian Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.64 (117.10% Upside)
$41.64 (117.10% Upside)
Blogger Sentiment
Bullish
GB:0K1R Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $499.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.02%
12-Months-Change
Fundamentals
Return on Equity
-51.88%
Trailing 12-Months
Asset Growth
134.79%
Trailing 12-Months
Company Description
Viridian Therapeutics
Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.
---
0K1R Company Deck
---
0K1R Earnings Call
Q1 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects significant progress and positive developments in the company's pipeline, particularly with the completion of enrollment in the THRIVE trial, a strong financial position, and positive regulatory interactions. However, there are challenges, such as the extended timeline for BLA submission and concerns about hearing impairment assessments in clinical trials.Read More>---
0K1R Stock 12 Month Forecast
Average Price Target
$41.64
▲(117.10% Upside)
Technical Analysis
Viridian Therapeutics
―
Annovis Bio
―
Kiniksa Pharmaceuticals
―
Seres Therapeutics
―
Ardelyx
―
Best Analysts Covering 0K1R
1 Year
1 Year Success Rate
21/37 ratings generated profit
1 Year Average Return
+5.12%
reiterated a buy rating 11 days ago
Copying Laura Chico's trades and holding each position for 1 Year would result in 56.76% of your transactions generating a profit, with an average return of +5.12% per trade.
---